Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Serina Therapeutics, Inc.

SER

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.

Last trade $1.41
Day change -$0.01 (-0.70%)
Day range $1.26 – $1.48
Volume 26,931
Market cap $38M

Open XASE

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$37.73M
Price / earnings
—
Price / book
2.71×
Price / sales
301.83×
EV / sales
171.99×
EV / EBITDA
-0.79×

Profitability

Earnings per share
-$1.03
Return on assets
-125.1%
Return on equity
-196.59%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.23×
Current ratio
4.62×
Quick ratio
4.62×
Cash ratio
4.28×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$22.84M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SER, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$125K$0$0$0$0$130K$0—
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$125K$0$0$0$0$130K$0—
Selling, general and administrative$3.36M$2.97M$3.08M$2.81M$2.74M$2.54M$2.91M—
Research and development$4.63M$3.82M$3.2M$3.4M$3.65M$3.15M$2.95M—
Total operating expenses$7.99M$6.78M$6.28M$6.21M$6.39M$5.7M$5.86M—
Operating income-$7.86M-$6.78M-$6.28M-$6.21M-$6.39M-$5.57M-$5.86M—
Interest expense-$204K-$203K-$189K-$198K-$6K-$9K$0—
Income before taxes-$7.91M-$6.36M-$6.89M-$3.32M-$4.6M-$6.46M-$4.82M—
Income taxes$0$0$7K$18K$0$0$0—
Net income-$7.91M-$6.36M-$6.9M-$3.34M-$4.6M-$6.46M-$4.82M—
Net income attributable to common shareholders-$7.91M-$8.93M-$6.94M-$3.59M-$4.69M-$6.57M-$4.81M—
EBITDA-$7.84M-$6.77M-$6.26M-$6.18M-$6.38M-$5.55M-$5.84M$56K
Basic earnings per share-$0.31-$0.55-$0.58-$0.34-$0.45-$0.66-$0.49—
Diluted earnings per share-$0.31-$0.55-$0.58-$0.34-$0.45-$0.66-$0.49—

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

Serina Therapeutics announced that its Chief Development Officer will present data on novel POZ-based lipid nanoparticles (LNPs) that overcome PEG immunogenicity issues. The company's POZ-lipid showed no antibody response in rat vaccine studies, unlike standard PEG-lipids which elicit immune responses. Serina is also advancing replacement ionizable lipids to address safety concerns in LNP formulations.

GlobeNewswire Inc.

Serina Therapeutics to Present at the 38th Annual Roth Conference

Serina Therapeutics, a clinical-stage biotech company, announced that CEO Steve Ledger will present at the 38th Annual Roth Conference on March 24, 2026. The company is developing its proprietary POZ Platform™ technology for drug optimization, with a focus on treating neurological diseases. Serina has a pipeline including SER-252 (POZ-apomorphine) for Parkinson's disease and has secured partnerships including a non-exclusive license agreement with Pfizer for lipid nanoparticle drug delivery applications.

Benzinga

Stock Market Today: Futures Drop Ahead Of 'Triple Witching' Session As Iran Threatens 'Zero Restraint'— FedEx, Super Micro In Focus (UPDATED)

U.S. stock futures declined on Friday with major indices down slightly ahead of 'triple witching' expiration. FedEx surged 10.43% on better-than-expected earnings and raised guidance, while Super Micro Computer plunged 23.61% after its co-founder was charged in an alleged AI technology export scheme to China. Planet Labs soared 17.25% and Scholastic gained 10.54% on strong earnings. Geopolitical tensions with Iran and energy market disruptions added to market uncertainty.

GlobeNewswire Inc.

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics announced the first patient enrollment in its Phase 1b registrational trial of SER-252, an investigational apomorphine therapy for advanced Parkinson's disease. The trial, initiated in Australia, evaluates safety, tolerability, pharmacokinetics, and preliminary efficacy. The company remains on track for first patient dosing in Q1 2026 and has FDA alignment on its 505(b)(2) NDA registrational pathway.

GlobeNewswire Inc.

Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event

Serina Therapeutics' CEO Steven Ledger will present at Tribe Public's webinar on February 4, 2026, discussing FDA initiatives and their impact on drug development. The company recently received FDA clearance for its SER-252 IND application for Parkinson's disease treatment and is initiating Phase 1b clinical activities in Australia.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.